Evoke Pharma Reports First Quarter 2022 Financial Results
10. Mai 2022 16:05 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today...
Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022
03. Mai 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...
Evoke Pharma Granted FDA Market Exclusivity for GIMOTI®
26. April 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List
19. April 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape
10. März 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
08. März 2022 16:05 ET
|
Evoke Pharma, Inc.
Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare...
Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
01. März 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022
24. Februar 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., and CHICAGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal...
GIMOTI® Commercialization Update
17. Februar 2022 08:30 ET
|
Evoke Pharma, Inc.
New Research Study Demonstrates Increased Acceptance Among Healthcare Providers Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com Expanded Coverage with recent...
Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI
02. Februar 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif. and CHICAGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI)...